Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0
|
作者：
Kurbacher, Christian M. [1 ]
Fischer, Lotta Ada [2 ]
Heinrich, Georg [3 ]
Herz, Susanne [1 ]
Schott, Alexander [1 ]
Kurbacher, A. Tabea [1 ]
Kurbacher, Jutta Anna [4 ]
Rudlowski, Christian [5 ]
Warm, Mathias R. [2 ]
机构：
[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany
[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany
[3] Praxis Gynakol Onkol, Furstenwalde, Germany
[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany
[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
552
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [31] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
    Agostinetto, E.
    Vian, L.
    Caparica, R.
    Bruzzone, M.
    Ceppi, M.
    Lambertini, M.
    Ponde, N.
    de Azambuja, E.
    ESMO OPEN, 2021, 6 (02)
  • [32] CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
    Migliaccio, Ilenia
    Bonechi, Martina
    McCartney, Amelia
    Guarducci, Cristina
    Benelli, Matteo
    Biganzoli, Laura
    Di Leo, Angelo
    Malorni, Luca
    CANCER TREATMENT REVIEWS, 2021, 93
  • [33] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Messina, Carlo
    Cattrini, Carlo
    Buzzatti, Giulia
    Cerbone, Luigi
    Zanardi, Elisa
    Messina, Marco
    Boccardo, Francesco
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) : 9 - 21
  • [34] ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
    Matikas, A.
    Lambertini, M.
    ESMO OPEN, 2021, 6 (01)
  • [35] Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer
    Bayraktar, Soley
    Batoo, Sameer
    Al-Hattab, Eyad
    Basu, Sandeep
    Okuno, Scott
    Gluck, Stefan
    FUTURE ONCOLOGY, 2020, 16 (32) : 2661 - 2672
  • [36] CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
    de Melo Gagliato, Debora
    Buzaid, Antonio C.
    Manuel Perez-Garcia, Jose
    Llombart, Antonio
    Cortes, Javier
    CANCERS, 2020, 12 (09) : 1 - 19
  • [37] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [38] Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience
    Decker, Thomas
    Seifert, Robert
    Bichler, Matthias
    Birtel, Andrea
    Fischer, Gerhard
    Nonnenbroich, Christoph
    Dechow, Tobias
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (09) : 443 - 448
  • [39] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR +/HER2-Breast Cancer at a Single Cancer Center
    Kovacevic, M. Milovic
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    BREAST, 2023, 68 : S46 - S46
  • [40] Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions
    Pla, H.
    Recalde Penabad, S.
    Vinas Villaro, G.
    Margeli Vila, M.
    Obadia Gil, V. L.
    Cirauqui Cirauqui, B.
    Del Barco Berron, S.
    J. Gil, M.
    Quiroga Garcia, V.
    Teruel-Garcia, I.
    Pernas Simon, S.
    Stradella, A.
    Esteve Gomez, A. M.
    Felip, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S660 - S660
12345